Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead presented positive clinical data for plozasiran at the 94th EAS Congress, showing that patients with moderate-to-severe renal or moderate hepatic impairment can take the standard 25 mg dose without adjustment. The data confirmed similar pharmacokinetic and pharmacodynamic responses in these impaired populations compared to controls, with no new safety signals identified.
Key figures
- Drug Name
- plozasiran
- Dose
- 25 mg
- Administration frequency
- once every three months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.